{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057228","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.242969+00:00","generated_at":"2026-06-02T21:54:03.176691+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024","bullets":["Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.","Chauche receives $480k base salary, 40% target bonus, and option grant valued at $2M (Black-Scholes).","Option vests over 4 years (25% cliff at 1 year, then monthly).","Severance: 6 months base salary (12 months during change in control), plus COBRA and equity acceleration.","Chauche previously CFO of Provention Bio and held roles at Alexion, Intercept, Novartis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057228","json":"https://secwatch.observer/filing/0001104659-24-057228.json","markdown":"https://secwatch.observer/filing/0001104659-24-057228.md","text":"https://secwatch.observer/filing/0001104659-24-057228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/tm2413539d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:54:03.176691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"374a5d7c02","claim":"Thierry Chauche was appointed as Chief Financial Officer at Sagimet Biosciences Inc..","evidence_excerpt":"On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ada8af2e4d","claim":"Joseph Oriti resigned as interim Principal Financial Officer and interim Principal Accounting Officer at Sagimet Biosciences Inc..","evidence_excerpt":"On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"interim Principal Financial Officer and interim Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}